As a part of the Cancer Moonshot Initiative, the NCI funded the Drug Resistance and Sensitivity Network (DRSN), a collaborative network of U54 centers of excellence focused on using advanced techniques and models to accelerate understanding of issues related to cancer resistance or extreme sensitivity to anticancer agents.

The NCI invites, through PA-18-591 in conjunction with Notice of Special Interest (NOSI, FY2018, FY2019, FY2020), the submission of request for administrative supplement to active NCI-funded grants and cooperative agreements. The goal is to encourage new interdisciplinary collaborations between outside (non-DSRN-supported) investigators and DSRN U54-supported investigators to perform research within the scientific scope(s) of their active parent grant(s) and/or cooperative agreement award(s). These collaborations between applicants and a DRSN U54 center are expected to lead to improved pre-clinical evaluations of novel discoveries in cancer drug resistance that could ultimately be tested in NCI-sponsored clinical trials.